Are polycystic ovaries associated with cardiovascular disease risk as polycystic ovary syndrome?

被引:23
作者
Engin-Uestuen, Yaprak
Ustun, Yusuf
Meydanli, M. Mutlu
Kafkasli, Ayse
Yetkin, Guelay
机构
[1] Inonu Univ, Sch Med, Dept Obstet & Gynecol, Malatya, Turkey
[2] Inonu Univ, Sch Med, Dept Microbiol, Malatya, Turkey
关键词
polycystic ovary syndrome; polycystic ovaries; C-reactive protein; insulin resistance;
D O I
10.1080/09513590600630447
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim. Our aim was to assess C-reactive protein (CRP) levels and insulin resistance in women with polycystic ovary syndrome (PCOS) or polycystic ovaries (PCO). Methods. The study population included 30 women with PCOS, 30 with PCO and 30 healthy controls. CRP and insulin resistance index (IRI) (fasting glucose/insulin) were measured. A receiver-operator characteristic (ROC) curve was constructed to determine the cut-off value of CRP to predict increased cardiovascular risk. Results. There were no statistically significant differences between the three groups with regard to age and body mass index. IRI was significantly lower in the PCOS group than in the PCO and control groups. No difference existed between the PCO and control groups. Median CRP levels in the control, PCO and PCOS groups were 0.75, 1.3 and 1.5 mg/l, respectively (p = 0.005). CRP could differentiate between women with and without increased cardiovascular risk at a cut-off value of 2.42 mg/l, with a sensitivity of 79% and a specificity of 81%. Conclusion. As in PCOS patients, women with PCO have higher serum CRP levels than healthy control women. This may contribute to increased cardiovascular disease risk in patients with PCO.
引用
收藏
页码:324 / 328
页数:5
相关论文
共 25 条
[1]   Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance [J].
Bahceci, M ;
Tuzcu, A ;
Canoruc, N ;
Tuzun, Y ;
Kidir, V ;
Aslan, C .
HORMONE RESEARCH, 2004, 62 (06) :283-287
[2]   Polycystic ovary syndrome - a systemic disorder? [J].
Balen, A ;
Rajkowha, M .
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2003, 17 (02) :263-274
[3]   High-sensitivity C-reactive protein: Clinical importance [J].
Bassuk, SS ;
Rifai, N ;
Ridker, PM .
CURRENT PROBLEMS IN CARDIOLOGY, 2004, 29 (08) :439-493
[4]   Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization [J].
Birdsall, MA ;
Farquhar, CM ;
White, HD .
ANNALS OF INTERNAL MEDICINE, 1997, 126 (01) :32-35
[5]   Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease [J].
Boulman, N ;
Levy, Y ;
Leiba, R ;
Shachar, S ;
Linn, R ;
Zinder, O ;
Blumenfeld, Z .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2160-2165
[6]  
Carmina E, 1997, HUM REPROD, V12, P905
[7]   Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome [J].
Chang, J ;
Azziz, R ;
Legro, R ;
Dewailly, D ;
Franks, S ;
Tarlatzis, BC ;
Fauser, B ;
Balen, A ;
Bouchard, P ;
Dahlgren, E ;
Devoto, L ;
Diamanti, E ;
Dunaif, A ;
Filicori, M ;
Homburg, R ;
Ibanez, L ;
Laven, J ;
Magoffin, D ;
Nestler, J ;
Norman, RJ ;
Pasquali, R ;
Pugeat, M ;
Strauss, J ;
Tan, S ;
Taylor, A ;
Wild, R ;
Wild, S ;
Ehrmann, D ;
Lobo, R .
FERTILITY AND STERILITY, 2004, 81 (01) :19-25
[8]   Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis [J].
Dunaif, A .
ENDOCRINE REVIEWS, 1997, 18 (06) :774-800
[9]   Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease [J].
Fenkci, V ;
Fenkci, S ;
Yimazer, M ;
Serteser, M .
FERTILITY AND STERILITY, 2003, 80 (01) :123-127
[10]   CLINICAL ASSESSMENT OF BODY HAIR GROWTH IN WOMEN [J].
FERRIMAN, D ;
GALLWEY, JD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1961, 21 (11) :1440-+